ALMDP — Medesis Pharma SA Income Statement
0.000.00%
Last trade - 00:00- €1.80m
- €5.08m
Annual income statement for Medesis Pharma SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | FAS | FAS | FAS | FAS | FAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.2 | 0.2 | 0.073 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.194 | 0.173 | 0.056 | -0.042 | -0.046 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.84 | 1.13 | 3.29 | 3.23 | 4.24 |
| Operating Profit | -1.64 | -0.932 | -3.21 | -3.23 | -4.24 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.08 | -0.991 | -3.21 | -3.23 | -4.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.93 | -0.791 | -2.65 | -2.75 | -3.96 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.93 | -0.791 | -2.65 | -2.75 | -3.96 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.93 | -0.791 | -2.65 | -2.75 | -3.96 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.316 | -0.19 | -0.606 | -0.628 | -0.797 |
| Dividends per Share |